{"id":"NCT01668966","sponsor":"Hoffmann-La Roche","briefTitle":"A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)","officialTitle":"A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-09","primaryCompletion":"2016-05-11","completion":"2016-05-11","firstPosted":"2012-08-20","resultsPosted":"2019-05-13","lastUpdate":"2019-05-13"},"enrollment":23,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra, Actemra"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week WA19926 (NCT01007435) core study. Eligible participants will be those who are expected to benefit from the study medicine based on the investigator's discretion.","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to approximately 104 weeks","effectByArm":[{"arm":"Tocilizumab","deltaMin":95.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":6,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":21},"commonTop":["Upper Respiratory Tract Infection","Dyslipidaemia","Upper respiratory tract infection","Tracheobronchitis","Vaginitis Bacterial"]}}